"PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis To 2024. The report is a helpful source of guidance for drug developers investors and new entrants to gain insights on changing market scenario develop business strategies for
growth. The study offers extensive analysis of risk factors pipeline analysis current & future market competition and annual revenues for the period 20142024. Global trends are provided in the research for countries in regions such as North America
Europe and Asia. The study also highlights forecast methodology assumptions and sources used to gather data. Tables and figures offer detailed insights on various factors and metrics. To Know More Ask for [email protected]
https://goo.gl/EZFzEp The report sheds a light on the current clinical and environmental needs and opportunities the launch will bring to drug developers. Moreover it explores diverse and robust MS pipeline. There are 13 products in phase three out of which the study analyzes nine. Out of these nine products eight products are expected to be launched during the forecast period. The market players will be benefited by understanding the impact of these products and changes in treatment algorithm. Tables offer detailed analysis of treatment guidelines and top three disease-modifying therapies prescribed for MS. The difficulty in diagnosis and management of MS is outlined and how it differs amongst the 10MM is explained. Tables offer insights on 10MM diagnosed prevalent cases and diagnosed incident cases based on sex and age for the period 20142024. The study offers an overview of MS such as epidemiology pathophysiology and etiology along with symptoms diagnosis and treatment guidelines. In addition disease background and risk factors are discussed. Global trends are outlined with the help of regions and its countries. In European region countries analyzed are France Germany Italy Spain and U.K. However Japan China and India are countries explored in the Asian region. Canada and U.S. are countries analyzed for North American region. Tables and figures offers an extensive analysis of diagnosis metrics of each country. These insights help market players in determining emerging countries and new opportunities in regions to devise strategies for expansion and widen consumer base. In addition market players can devise strategies for sales and marketing to consolidate their position identify investment opportunities and form strategic partnerships. The report offers a comprehensive analysis of major injectable product brands and small molecule product brands. Betaseron Avonex Rebif Copaxone Tysabri Lemtrada and Plegridy are major injectable product brands analyzed in the study. However Gilenya Aubagio and Tecfidera are major small molecules product brands explored in the research. Tables offer detailed analysis of above brands. Moreover unmet needs and gap analysis are discussed in the research to assist market players to identify opportunities and devise strategies for the growth. Pipeline assessment is carried out in the report based on clinical trial mappings clinical trials by country and promising drugs in clinical development. Zinbryta Ocrelizumab Ofatumumab Opicinumab Nerventra Masitinib Siponimod Ozanimod and Ponesimod are drugs in clinical development. In addition last stage therapeutic vaccines are also analyzed. The report offers an extensive analysis of drug developers including Biogen Teva Sanofi Bayer Novartis Roche and Merck Serono. Tables offer insights on product portfolio and SWOT analysis of each market player. Driver and barriers are also outlined in the study to help market players gain stronghold in the market. Forecasts are made and key events are outlined to help industry players investors and stakeholders to devise strategies to gain competitive edge in the future.